The Congressional Budget Office (CBO) is calling for more research into the No Surprises Act to evaluate the law’s effect on heal | The nonpartisan office is seeking more information on the law’s impact on healthcare prices, network participation, ownership structures and more.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
A new ad campaign takes aim at the "misaligned incentives" in the No Surprises Act arbitration process, arguing they "create a…
More than 500 hospitals falling short on price transparency requirements have received warnings from the federal government since…
After years of investigation, the outgoing chairman of the Senate Health, Education, Labor and Pensions Committee has released…
Fewer than a third of people with commercial coverage say that their plans represent a "trusted partner" in their health,…
A new analysis from the Office of Inspector General found a similar net cost for drugs through vertically-integrated Part D plans…
Patient collections are playing a bigger and bigger role in health systems’ total revenues, bringing a new focus on the…
